A Phase 3 interventional study of insulin degludec and sitagliptin in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 93 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-03.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 23rd largest by enrollment, is one of 12 that started in 2010, is one of 49 in phase 3, and was the 7th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Gan and Lee Pharmaceuticals, USA · Sites in Germany
Ages 18–70
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–70
Yanbing Li
Ages 18–70
Tonghua Dongbao Pharmaceutical Co.,Ltd
Ages 18–75
By country, each count listing its studies:
insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 50 · Phase 4 8
First in 2006; this study’s year is marked. 12 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 458 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 384 across the 70 interventional studies. Of the 64 that completed or were terminated, 51 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 70 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 107th largest by enrollment of the 428 interventional ones that give a count, is one of 25 that started in 2010, is one of 187 in phase 3, and was the 184th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing insulin degludec in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial will be conducted in Africa, Asia, North America and South America. The aim of this clinical trial is to compare NN1250 (insulin degludec) with sitagliptin, as add-on to subject's own current oral antidiabetic (OAD) treatment, in subjects with type 2 diabetes inadequately controlled with 1-2 OADs (metformin, sulphonylurea, glinides or pioglitazone).
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 458 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: insulin degludec
Drug: sitagliptin
Injected under the skin once daily for 26 weeks. The doses will be individually adjusted.
Sitagliptin tablets administered orally once a day at the same time every day for 26 weeks
Change in Glycosylated Haemoglobin (HbA1c)
Change from baseline in HbA1c after 26 weeks of treatment
Time frame: Week 0, Week 26
Change in Fasting Plasma Glucose (FPG)
Change from baseline in FPG after 26 weeks of treatment
Time frame: Week 0, Week 26
The trial was conducted at 78 sites in 7 countries: Argentina (2 sites), Canada (11 sites), India (8 sites), Mexico (2 sites), South Africa (3 sites), Turkey (5 sites) and the United States (47 sites).
| Milestone | IDeg OD | DPP-IV Inhibitor |
|---|---|---|
| Started | 229 | 229 |
| Exposed | 226 | 228 |
| Completed | 174 | 174 |
| Not completed | 55 | 55 |
| Withdrew: Adverse event | 9 | 2 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Protocol violation | 7 | 12 |
| Withdrew: Withdrawal criteria | 3 | 5 |
| Withdrew: Unclassified | 36 | 35 |
Change from baseline in HbA1c after 26 weeks of treatment
| percentage of glycosylated haemoglobin | IDeg OD | DPP-IV Inhibitor |
|---|---|---|
| Change in Glycosylated Haemoglobin (HbA1c) | -1.56 ± 1.09 | -1.22 ± 1.16 |
Change from baseline in FPG after 26 weeks of treatment
| mmol/L | IDeg OD | DPP-IV Inhibitor |
|---|---|---|
| Change in Fasting Plasma Glucose (FPG) | -3.22 ± 3.17 | -1.39 ± 3.11 |
Collected over The adverse events were collected in a time frame of 26 weeks + 7 days follow-up. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IDeg OD | — | 14/226 (6.2%) | 44/226 (19.5%) |
| DPP-IV Inhibitor | — | 10/228 (4.4%) | 53/228 (23.2%) |
| Event | IDeg OD | DPP-IV Inhibitor |
|---|---|---|
| Acute myocardial infarctionCardiac disorders | 1/226 | 0/228 |
| Cardiac failure congestiveCardiac disorders | 1/226 | 0/228 |
| CardiomyopathyCardiac disorders | 1/226 | 0/228 |
| Myocardial infarctionCardiac disorders | 1/226 | 0/228 |
| ConstipationGastrointestinal disorders | 1/226 | 0/228 |
| CholelithiasisHepatobiliary disorders | 1/226 | 0/228 |
| CellulitisInfections and infestations | 1/226 | 0/228 |
| DiverticulitisInfections and infestations | 1/226 | 0/228 |
| Lobar pneumoniaInfections and infestations | 1/226 | 0/228 |
| PneumoniaInfections and infestations | 1/226 | 0/228 |
| Event | IDeg OD | DPP-IV Inhibitor |
|---|---|---|
| HeadacheNervous system disorders | 24/226 | 15/228 |
| DiarrhoeaGastrointestinal disorders | 13/226 | 19/228 |
| NasopharyngitisInfections and infestations | 13/226 | 18/228 |
| NauseaGastrointestinal disorders | 8/226 | 14/228 |
The full analysis set (FAS) included all randomised patients except for 11 subjects whose site was closed (4 subjects with IDeg; 7 subjects with DPP-IV group/arm). For 4 subjects each in IDeg OD and DPP-IV inhibitor arm, the fasting plasma glucose (FPG) values were missing at baseline.
| Age, Continuous(years) | IDeg OD | DPP-IV Inhibitor | Total |
|---|---|---|---|
| Mean | 56.4 ± 10.2 | 54.9 ± 11.4 | 55.7 ± 10.9 |
| Sex: Female, Male(Participants) | IDeg OD | DPP-IV Inhibitor | Total |
|---|---|---|---|
| Female | 84 | 101 | 185 |
| Male | 141 | 121 | 262 |
| Glycosylated haemoglobin (HbA1c)(percentage of glycosylated haemoglobin) | IDeg OD | DPP-IV Inhibitor | Total |
|---|---|---|---|
| Mean | 8.8 ± 1.0 | 9.0 ± 1.0 | 8.9 ± 1.0 |
| Fasting plasma glucose (FPG)(mmol/L) | IDeg OD | DPP-IV Inhibitor | Total |
|---|---|---|---|
| Mean | 9.4 ± 2.6 | 9.9 ± 3.1 | 9.7 ± 2.9 |
The record gives a start of Jan 2010, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2015, 5 years after primary completion. A results delay was requested in Feb 2011.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin degludec · Sitagliptin